254 related articles for article (PubMed ID: 26241209)
1. Computational and Practical Aspects of Drug Repositioning.
Oprea TI; Overington JP
Assay Drug Dev Technol; 2015; 13(6):299-306. PubMed ID: 26241209
[TBL] [Abstract][Full Text] [Related]
2. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.
Shameer K; Readhead B; Dudley JT
Curr Top Med Chem; 2015; 15(1):5-20. PubMed ID: 25579574
[TBL] [Abstract][Full Text] [Related]
3. A survey of current trends in computational drug repositioning.
Li J; Zheng S; Chen B; Butte AJ; Swamidass SJ; Lu Z
Brief Bioinform; 2016 Jan; 17(1):2-12. PubMed ID: 25832646
[TBL] [Abstract][Full Text] [Related]
4. Drug repositioning: computational approaches and research examples classified according to the evidence level.
Vogrinc D; Kunej T
Discoveries (Craiova); 2017 Jun; 5(2):e75. PubMed ID: 32309593
[TBL] [Abstract][Full Text] [Related]
5. Drug repositioning for rare diseases: Knowledge-based success stories.
Scherman D; Fetro C
Therapie; 2020 Apr; 75(2):161-167. PubMed ID: 32164975
[TBL] [Abstract][Full Text] [Related]
6. Revisiting Repurposing.
Sharlow ER
Assay Drug Dev Technol; 2016 Dec; 14(10):554-556. PubMed ID: 27982703
[TBL] [Abstract][Full Text] [Related]
7. Computational Drug Repositioning: A Lateral Approach to Traditional Drug Discovery?
Sahu NU; Kharkar PS
Curr Top Med Chem; 2016; 16(19):2069-77. PubMed ID: 26881717
[TBL] [Abstract][Full Text] [Related]
8. In vitro screening for drug repositioning.
Wilkinson GF; Pritchard K
J Biomol Screen; 2015 Feb; 20(2):167-79. PubMed ID: 25527136
[TBL] [Abstract][Full Text] [Related]
9. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
10. eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs.
Brylinski M; Naderi M; Govindaraj RG; Lemoine J
J Mol Biol; 2018 Jul; 430(15):2266-2273. PubMed ID: 29237557
[TBL] [Abstract][Full Text] [Related]
11. In silico drug repositioning: what we need to know.
Liu Z; Fang H; Reagan K; Xu X; Mendrick DL; Slikker W; Tong W
Drug Discov Today; 2013 Feb; 18(3-4):110-5. PubMed ID: 22935104
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in drug repositioning for the discovery of new anticancer drugs.
Shim JS; Liu JO
Int J Biol Sci; 2014; 10(7):654-63. PubMed ID: 25013375
[TBL] [Abstract][Full Text] [Related]
13. A review of validation strategies for computational drug repositioning.
Brown AS; Patel CJ
Brief Bioinform; 2018 Jan; 19(1):174-177. PubMed ID: 27881429
[TBL] [Abstract][Full Text] [Related]
14. Drug Repositioning: A Unique Approach to Refurbish Drug Discovery.
Kale MA; Shamkuwar PB; Mourya VK; Deshpande AB; Shelke PA
Curr Drug Discov Technol; 2022; 19(1):e140122192307. PubMed ID: 33726652
[TBL] [Abstract][Full Text] [Related]
15. From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns.
Salentin S; Adasme MF; Heinrich JC; Haupt VJ; Daminelli S; Zhang Y; Schroeder M
Sci Rep; 2017 Sep; 7(1):11401. PubMed ID: 28900272
[TBL] [Abstract][Full Text] [Related]
16. Computational Drug Repurposing: Current Trends.
Karaman B; Sippl W
Curr Med Chem; 2019; 26(28):5389-5409. PubMed ID: 29848268
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing in rare diseases: Myths and reality.
Fetro C; Scherman D
Therapie; 2020 Apr; 75(2):157-160. PubMed ID: 32241561
[TBL] [Abstract][Full Text] [Related]
18. Computational drug repositioning for cancer therapeutics.
Jiao M; Liu G; Xue Y; Ding C
Curr Top Med Chem; 2015; 15(8):767-75. PubMed ID: 25732789
[TBL] [Abstract][Full Text] [Related]
19. Additional Neural Matrix Factorization model for computational drug repositioning.
Yang X; Zamit L; Liu Y; He J
BMC Bioinformatics; 2019 Aug; 20(1):423. PubMed ID: 31412762
[TBL] [Abstract][Full Text] [Related]
20. Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds.
Carrella D; Manni I; Tumaini B; Dattilo R; Papaccio F; Mutarelli M; Sirci F; Amoreo CA; Mottolese M; Iezzi M; Ciolli L; Aria V; Bosotti R; Isacchi A; Loreni F; Bardelli A; Avvedimento VE; di Bernardo D; Cardone L
Oncotarget; 2016 Sep; 7(37):58743-58758. PubMed ID: 27542212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
